Milestone Scientific announced it will hold a conference call on November 13, 2026, to discuss its financial results for the third quarter ended September 30, 2026. The call will also cover corporate progress and other developments related to its computerized drug delivery technology. Investors can join via phone or webcast, with a replay available until November 27. This event provides insight into Milestone's ongoing innovation in medical injection technology and its market expansion efforts.
Milestone Scientific's upcoming Q3 2026 financial results call is announced as context for readers. For those tracking the health sector, here is Pluang's market snapshot as of Nov 12, 2026 04:11 WIB: Among 150 priced US health stocks, 87 advanced and 61 declined. Notable movers include ABEO at USD 2.25 with a 1-day change of -8.35% and Pluang order activity showing 62% Sell / 38% Buy, LQDA at USD 55.04 up 7.08% with 46% Sell / 54% Buy, and NUWE at USD 5.58 up 6.49% but with 100% Sell orders and a typical hold time of 32 days on Pluang.
Ashland Inc.'s board of directors declared a quarterly cash dividend of $0.42 per share, payable on December 15, 2026, to shareholders of record as of December 1, 2026. This dividend reflects the company's ongoing commitment to returning value to sha...
AeroVironment secured a $405 million international order for its LOCUST X3 high-energy laser weapon systems, enhancing counter-drone defense capabilities in the Middle East amid rising regional security threats. Following the announcement, AeroVironm...
Vestas Wind Systems reported Q3 2026 earnings per share of $0.13 and revenue of $6.34 billion, both below analyst expectations. The company's profit was impacted by weak sales volume and a broken turbine blade. Following the earnings miss, Vestas' sh...
The global beverage market is projected to grow from $2.03 trillion in 2026 to $2.78 trillion by 2032, at a CAGR of 5.35%. Growth is fueled by rising demand for nonalcoholic and functional beverages, convenience packaging, and premium products for sp...
DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...
